Stelara, a top-selling psoriasis drug by Johnson & Johnson (@JNJNews), has seen a consistent price increase since its introduction to the market. Since 2012, the drugs price has increased by at least 4.8% annually, leading to an overall price rise of 184%. This escalating cost has raised serious concerns about the drugs affordability for patients. The issue has been a hot topic of discussion among the Health, Education, Labor, and Pensions (HELP) Committee Democrats (@HELPCmteDems) and the GOP HELP Committee (@GOPHELP). <\/p>\n
According to data from Simply Wall St, Johnson & Johnsons stock price, market cap, and recent performance are highlighted. The report also includes insights from equity analysts on the companys drug pipeline and revenue growth. Despite being a significant player in the pharmaceutical industry, JNJ has underperformed in the US Pharmaceuticals industry and the US Market over the past year. The Consumer Health segment of the company is also profiled on the site. <\/p>\n
Despite the underperformance in certain sectors, Johnson & Johnson announced a strong finish to 2023. As reported on Investing.com, their fourth-quarter worldwide sales reached $21.4 billion, marking a 7.2% increase. The companys quarterly results just slightly exceeded Wall Street expectations. <\/p>\n
The consistent price increase of Stelara has been a cause for concern among patients and healthcare advocates. Psoriasis is a chronic condition, and many patients require long-term medication such as Stelara to manage their symptoms. The significant increase in the drugs price puts a financial burden on patients, particularly those without comprehensive medical insurance. <\/p>\n
The HELP Committee Democrats and the GOP HELP Committee have been engaged in discussions about the rising cost of Stelara. The committees are concerned about the impact of the price increase on patients and are exploring potential solutions to address this issue. While these discussions are ongoing, it is clear that the rising cost of Stelara is an issue that requires immediate attention. <\/p>\n
The rising cost of medication is a pressing issue that affects patient accessibility to necessary treatments. For chronic conditions like psoriasis, the affordability of long-term medication is crucial. As discussions continue among various stakeholders, it is hoped that effective solutions will be found to ensure that patients can access and afford the medication they need. <\/p>\n
<\/p>\n
See original here: Stelara, a top-selling psoriasis drug by Johnson & Johnson (@JNJNews), has seen a consistent price increase since its introduction to the market. Since 2012, the drugs price has increased by at least 4.8% annually, leading to an overall price rise of 184%. This escalating cost has raised serious concerns about the drugs affordability for patients Continue reading
\nRising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"